<?xml version='1.0' encoding='utf-8'?>
<document id="16455804"><sentence text="Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid."><entity charOffset="90-102" id="DDI-PubMed.16455804.s1.e0" text="fexofenadine" /><entity charOffset="107-117" id="DDI-PubMed.16455804.s1.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.16455804.s1.e0" e2="DDI-PubMed.16455804.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16455804.s1.e0" e2="DDI-PubMed.16455804.s1.e1" /></sentence><sentence text="Fexofenadine, a nonsedating antihistamine drug, is effective for the treatment of seasonal allergic rhinitis and chronic urticaria"><entity charOffset="0-12" id="DDI-PubMed.16455804.s2.e0" text="Fexofenadine" /></sentence><sentence text=" Simultaneous administration of probenecid increases the plasma concentration of fexofenadine due to an inhibition of its renal elimination in healthy volunteers (Clin Pharmacol Ther 77:17-23, 2005)"><entity charOffset="81-93" id="DDI-PubMed.16455804.s3.e0" text="fexofenadine" /></sentence><sentence text=" The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process"><entity charOffset="107-119" id="DDI-PubMed.16455804.s4.e0" text="fexofenadine" /><entity charOffset="124-134" id="DDI-PubMed.16455804.s4.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.16455804.s4.e0" e2="DDI-PubMed.16455804.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16455804.s4.e0" e2="DDI-PubMed.16455804.s4.e1" /></sentence><sentence text=" The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2)"><entity charOffset="15-27" id="DDI-PubMed.16455804.s5.e0" text="fexofenadine" /></sentence><sentence text=" Only hOAT3-HEK showed a significantly greater accumulation of fexofenadine than that in vector-HEK, which was saturable with K(m) and V(max) values of 70"><entity charOffset="63-75" id="DDI-PubMed.16455804.s6.e0" text="fexofenadine" /></sentence><sentence text="2 microM and 120 pmol/min/mg protein, respectively" /><sentence text=" Inhibition potency of probenecid for the uptake of fexofenadine was compared between hOAT3 and organic anion-transporting peptide 1B3 (hOATP1B3), a transporter responsible for the hepatic uptake of fexofenadine (Drug Metab Dispos 33:1477-1481, 2005)"><entity charOffset="23-33" id="DDI-PubMed.16455804.s8.e0" text="probenecid" /><entity charOffset="52-64" id="DDI-PubMed.16455804.s8.e1" text="fexofenadine" /><entity charOffset="199-211" id="DDI-PubMed.16455804.s8.e2" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.16455804.s8.e0" e2="DDI-PubMed.16455804.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16455804.s8.e0" e2="DDI-PubMed.16455804.s8.e1" /><pair ddi="false" e1="DDI-PubMed.16455804.s8.e0" e2="DDI-PubMed.16455804.s8.e2" /><pair ddi="false" e1="DDI-PubMed.16455804.s8.e1" e2="DDI-PubMed.16455804.s8.e1" /><pair ddi="false" e1="DDI-PubMed.16455804.s8.e1" e2="DDI-PubMed.16455804.s8.e2" /></sentence><sentence text=" The K(i) values were determined to be 1" /><sentence text="30 and 130 microM for hOAT3 and hOATP1B3, respectively, with Hill coefficients of 0" /><sentence text="76 and 0" /><sentence text="64, respectively" /><sentence text=" The K(i) value of probenecid for hOAT3, but not for hOATP1B3, was significantly lower than the maximum unbound plasma concentration of probenecid at clinical dosages"><entity charOffset="19-29" id="DDI-PubMed.16455804.s13.e0" text="probenecid" /><entity charOffset="136-146" id="DDI-PubMed.16455804.s13.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.16455804.s13.e0" e2="DDI-PubMed.16455804.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16455804.s13.e0" e2="DDI-PubMed.16455804.s13.e1" /></sentence><sentence text=" These results suggest that the renal drug-drug interaction between fexofenadine and probenecid is probably explained by an inhibition of the renal uptake of fexofenadine via hOAT3, at least in part"><entity charOffset="68-80" id="DDI-PubMed.16455804.s14.e0" text="fexofenadine" /><entity charOffset="85-95" id="DDI-PubMed.16455804.s14.e1" text="probenecid" /><entity charOffset="158-170" id="DDI-PubMed.16455804.s14.e2" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.16455804.s14.e0" e2="DDI-PubMed.16455804.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16455804.s14.e0" e2="DDI-PubMed.16455804.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16455804.s14.e0" e2="DDI-PubMed.16455804.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16455804.s14.e1" e2="DDI-PubMed.16455804.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16455804.s14.e1" e2="DDI-PubMed.16455804.s14.e2" /></sentence><sentence text="" /></document>